Dig into something you heard this week?
Drop a link — a podcast, a YouTube clip, an article, a post — or paste a screenshot. The agents pull out what’s being claimed and get you oriented before you believe it, share it, or let it stick. Or just ask about this week’s coverage.
Top claims
The same promise, three rounds running
Tariffs will be good for consumers — prices will come down within the year.
Prices on affected goods rose 4.1% in the first year; the first category-level declines arrived in month 15.
Prices rose for 14 months before any fell.
Today's claim runs on the same one-step logic — tariff, then domestic substitution, then lower prices. Three rounds of receipts show the middle step took over a year to appear, when it appeared at all.
Who actually paid last time
Customs receipts from the 2018–2021 rounds show importers, not foreign exporters, paid 93% of the tariff bill — about $51B of it passed through to U.S.…
What would have to be true
For prices to fall within a year, domestic factories would need spare capacity in the tariffed categories now. Utilization data puts the affected categories at 87% — near the level where new orders raise prices instead of volumes.

Iran ceasefire keeps verification monitors in place for the first 90 days.
Allied coverage is reading the same text differently
European wire services frame the 90-day verification window as the *centerpiece* of the deal; U.S.…

This year's El Niño anomalies are still inside the 1997 / 2015 envelope.
Anomaly is real; 'historic' is doing the heavy lifting
The 3-month running mean is high but not a record. The 1997 and 2015 events both peaked higher on the same Niño 3.…

The 'seed oils are inflammatory' claim conflates lab markers with disease outcomes.
Eleven of fourteen reviews disagree
Recent peer-reviewed nutrition reviews don't find the causal link the claim asserts at typical intake levels. The narrower oxidation-product question is real but distinct.
GLP-1 prescriptions for non-diabetic use now outnumber the diabetic indication 3:1.
The denominator matters here
The 3:1 ratio is on *new* prescriptions in commercial insurance — Medicare, Medicaid, and the cash-pay segment all skew the other direction.

The 'AI hiring freeze' chart only counts W-2 hires — contract data flips it.
The dataset only covers W-2 hires
The chart making the rounds is W-2 hires only. Stitching contract roles back in (BLS contractor data + Upwork) re-traces the post-2023 line with a positive slope.

The 'microplastics in blood' figure traces to a 22-person pilot the authors flagged.
A 22-person pilot its own authors flagged
The pilot's authors explicitly warned against generalising the result. Larger follow-ups are running but haven't published; the headline figure is still that 2022 pilot.